Journalist Hunt

JournalistsPricingBlogs
LoginSign up

Yasuyuki Kakihana - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Yasuyuki Kakihana's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Yasuyuki Kakihana

Yasuyuki Kakihana

Verified

Beats

Primary beats

Health

Secondary beats

PoliticsSportsCancerBarsInterviewsAsWellnessMental HealthGovernmentThought StyleSpot NewsTv ShowsManifestingEcological ConcernsGeneralTravelEnvironmentalCeleb QHealthcare Systems

Final Covers

beauty wellnessFitness

Doesn’t Cover

I havent found a topic I wont cover yet

Journalist Type

-

Seniority Positions

-

Medium Formats

-

Content

Total articles 3

  • Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

    By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima

    Mar. 31, 2020

  • Is early goal-directed therapy associated with a higher risk of adverse events?

    By Ahmad Sabry Saleh, Yasuyuki Kakihana

    Nov. 27, 2018

  • Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial

    By Yasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, Masaki Okajima

    Mar. 31, 2020

As seen in

Journal Of Intensive Care,The Lancet

Company Info

, Kagoshima Prefecture, Japan

+81 992-75-5111

Founded: